Related Experiment Video

Updated: Sep 18, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K

Breaking Cancer's Momentum: CDK4/6 Inhibitors and the Promise of Combination Therapy

Yanbiao Liu1, Seohyun Park1, Yan Li1,2

  • 1School of Science, Auckland University of Technology, Auckland 1010, New Zealand.

Cancers
|June 26, 2025
PubMed

Insights

Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors offer a novel cancer therapy by halting cell division. Research is expanding their use and exploring new resistance mechanisms for improved cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • CDK4/6 inhibitors are a new class of cancer therapeutics.
  • They target CDK4/6 complexes to induce G1 cell cycle arrest.
  • Currently used for ER+/HER2- breast cancer, often with hormone antagonists.

Purpose of the Study:

  • To review the mechanisms of CDK4/6 inhibitors in cancer treatment.
  • To explore novel combination therapies and applications beyond breast cancer.
  • To discuss emerging resistance mechanisms and their broader cellular effects.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of recent research on resistance mechanisms.
  • Synthesis of information on cellular metabolism, autophagy, and the tumor microenvironment.

Main Results:

  • CDK4/6 inhibitors induce cell cycle arrest, showing clinical success in breast cancer.
  • New resistance mechanisms impact cell metabolism, autophagy, and the tumor microenvironment.
  • Variable cellular responses and rapid resistance development are key challenges.

Conclusions:

  • CDK4/6 inhibitors are a promising cancer therapy with expanding applications.
  • Understanding resistance mechanisms is crucial for overcoming treatment limitations.
  • Future strategies may involve novel combinations and personalized approaches for enhanced efficacy.
Keywords:
CDK 4/6 inhibitorcancer treatmentcombination therapy

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.9K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.0K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.7K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
675